Journal for ImmunoTherapy of Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2022-11-09 明日之星

审稿速度:2.0 | 投稿命中率:50.0
经验分享：期刊效率非常高，对国人也比较友好
16-Aug-2022 Submitted
06-Sep-2022 Major Revision，大概1个月修回
24-Oct-2022 Minor Revision
03-Nov-2022 Accept

90 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2022-05-20 ms1000001524948647

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：免疫;癌症
经验分享：2月1日投稿；
2月28日开始awaiting reviewers score,中间select了两轮审稿人；
5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation;
3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定；
第二天早上5点收到主编邮件，3个审稿人，小修。

现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！

109 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2022-02-07 hujianjun92

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫
经验分享：经验分享：2021.7.3投稿
2021.9.14大修
2022.1.9修回
2022.1.28接收
杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！

158 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2023-05-20 1321f2f792m 来自陕西省

修回后awaiting recommendation已经5天了，一直没变状态，有点慌。

58 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2023-06-12 osmataku 来自北京

投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了

34 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2022-03-29 princesun083

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：RNA生物学;肿瘤免疫
经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。

293 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2023-02-17 DDPP 来自广东省

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤免疫
经验分享：目前很困难了

0 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2022-04-28 123cddb2m15暂无昵称

十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊

105 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2020-03-12 西西131401

Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊

189 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190771, encodeId=73611190e7198, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：经验分享：2021.7.3投稿 2021.9.14大修 2022.1.9修回 2022.1.28接收 杂志的状态有点迷惑人，建议投搞之后不要刷状态，不然心态会崩，安心做自己的工作，等待邮件通知即可，大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a65e3120259, createdName=hujianjun92, createdTime=Mon Feb 07 17:08:23 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1206787, encodeId=066a1206e87fe, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：RNA生物学;肿瘤免疫 经验分享：2021年9月9日投稿，11月26日大修（给了两个月修回，四个审稿人，审稿意见太多了，不过很专业，按照要求补实验和修改后明显感觉文章更完整和深入了），2022年1月25日趁着最后期限修回，3月10日小修，3月17日修回，3月28日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Tue Mar 29 07:46:13 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115003, encodeId=5112211500396, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：目前很困难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Feb 17 00:06:36 CST 2023, time=2023-02-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1215204, encodeId=52b912152047e, content=十天从awaiting reviewer scores 变成了awaiting recommendation是什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=605a2438688, createdName=123cddb2m15暂无昵称, createdTime=Thu Apr 28 01:48:53 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586482, encodeId=66b658648216, content=Awaiting section editor handling-Awaiting reviewer selection-Awaiting reviewer assigned-Awaiting recommendation-Awaiting decision-reject，历经一周时间，这是内审没过，那送外审是什么状态呢？这里的reviewer 一直指的是editor，这样很容易误导作者以为送外审了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJFrt3WdV0nESgrJiaELZI7Xj0uNOFjt052Thc8Aomg4thuSWnkyzaZYqIJhPLkIgWaIbswDxUW2sg/132, createdBy=608d1996208, createdName=西西131401, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京)]

2023-03-05 osmataku 来自北京

刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。

46 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务